Kasinger James R. sold 10,400 shares of CRISPR Therapeutics AG at $60.24 for −$626k on Sep 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
General Counsel and Secretary
General Counsel and Secretary
Filed Sep 24, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$626,459.60Shares × reported price
Shares traded
10,400Common Shares
Price per share
$60.24Reported price. Read footnotes for ranges.
% of reported position traded
9.89%This security and ownership context
Holdings after
94,784Direct
Trade date
Sep 22, 2026Sell
Filed
Sep 24, 2026, 5:35 PM ET2-day reporting delay
Accession
0001193125-26-401237Code S · Transaction 229267
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 105,184 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 22, 2026Option exercise10,400$13.62$141,648Trade 229266
Sep 22, 2026Option exercise10,400$0.00$0Trade 229268
3 transaction rows in this filing. Joint filers share the same rows.

CRSP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CRSP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −0.5%30d −11%90d180d1y

Footnotes in full

F1: Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.